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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the role of splinting and the optimal treatment strategy for the non-operative management of DDH in children under
six months of age. To identify if there are particular subgroups of patients for whom the optimal management strategy may differ.
B A C K G R O U N D
Description of the condition
Developmental dysplasia of the hip (DDH) is a common paedi-
atric condition, with a variable incidence that appears to be based
on ethnicity (Loder 2011). Within the UK, USA, and Australia,
the incidence is approximately 10 per 1000 live births, with 1
in 1000 hips being dislocated at birth (Storer 2006). Amongst
Native Americans, however, the incidence may be more than 10
times higher, and amongst African people it is believed to be ex-
tremely rare (Loder 2011). In the UK, abnormalities of the hip are
screened for as part of the Newborn and Infant Physical Exami-
nation (NIPE) programme (UK National Screening Programme
2013). A Cochrane systematic review has assessed screening for
DDH (Shorter 2013). DDH encompasses a spectrum of abnor-
malities, which range from delayed physiological development of
the hip, through to acetabular deficiency, subluxation, and dislo-
cation of the hip. It is more common in females, babies in the
breech position in the third trimester, firstborn children, oligohy-
dramnios (not enough amniotic fluid during pregnancy), and in
those with a family history of the condition (Storer 2006).
The management strategy for DDH depends on the child’s age
and the severity of the disease. In children under six months of
age the usual strategy, once abnormalities are identified, is to apply
an abduction splint, such as a Pavlik harness (Mubarak 2003),
and monitor the disease progression with serial ultrasound scans
(Cooper 2014). If this is successful, no further intervention is
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required. If the child fails to respond to splinting, then they are
managed with surgery to gently reduce (relocate) the hip, which
may be achieved closed (i.e. without surgical incisions) or may
necessitate a formal surgical approach to achieve reduction of the
hip. There is no consensus on the length of time splinting should
be pursued before reverting to surgical intervention, but reports
of treatment length vary from 11 weeks to 28 weeks (Tomlinson
2016).
The paediatric hip undergoes a variety of changes in normal phys-
iological development. Indeed, evidence has suggested that some
hips that are abnormal in newborns may become normal without
any intervention at all (Barlow 1962; Gardiner 1990; Shipman
2006). Therefore, there is a balance between undertreating and
overtreating this condition. This is especially important because
therapy with splints risks localised blood supply damage known
as avascular necrosis (AVN) and femoral nerve palsy (Murnaghan
2010; Pollet 2010). The risk of AVN using a splint is in the re-
gion of 1% (Cashman 2002; Eidelman 2003), although some re-
ports may be as high as 11% (Suzuki 2000). Furthermore, treating
newborns in splints can cause considerable upset to new parents
and can interfere with the bond between mothers and their new
baby (Gardner 2005). Parents are also concerned about the use of
splints interfering with ‘tummy time’ as ‘tummy time’ can affect
both fine and gross motor skills.
Decisions regarding the treatment of DDH are typically made
based on the ultrasonographic appearance of the hips. The most
commonly used classification system is based on a static ultrasound
image (Graf 2006; see Table 1). Other types of ultrasound assess-
ment are also used, such as the dynamic assessment popularised by
Harcke 1984; however, these techniques are typically combined
with a static ultrasound assessment.
Patients with an alpha angle above 60 degrees are considered nor-
mal, and are classified as a Graf I hip (Graf 2006). Patients with
an alpha angle from 50 to 59 degrees and under the age of three
months are classified as Graf IIa (Karnik 2007); they are usually
managed with ultrasound follow-up alone to ensure resolution.
Children with a persistent alpha angle from 50 to 59 degrees and
older than three months are classified as Graf IIb. In the UK, chil-
dren with Graf IIb hips who are under the age of six months are
frequently managed with a splint, in conjunction with ultrasound
follow-up. Graf IIb hips constitute the most common reason to
use a splint in the treatment of DDH; however, debate exists as to
whether treating Graf IIb hips has any bearing on the outcome,
with many centres ceasing to use splints for this reason. Those
with more severe dysplasia (Graf III hips) or those that are dislo-
cated (Graf IV hips) routinely receive treatment in the form of an
abduction splint, but it is unclear when this should commence,
which splint is best, or the extent to which splints offer additional
benefit over natural history alone (Tomlinson 2016).
Therefore, it is important to establish the best practice for the non-
surgical management of children with DDH under six months
old, and identify the extent to which the intervention with a splint
alters the prognosis of disease.
Description of the intervention
A variety of splints are used to abduct and flex the hips into the
desired position.
The most commonly used splint is the Pavlik harness. This splint
promotes a dynamic reduction; that is, children are free to move
their legs within the range permitted by the splint. This is thought
to provide a more gentle reduction than other splints that fix the
legs in a predefined position, thereby potentially lowering the risk
of complications. Pavlik harnesses are also readily adjustable to the
size of the infant and are more convenient to store (pack flat) than
fixed abduction splints.
Fixed abduction splints (e.g. Von Rosen splint) are less commonly
used, with greater concerns about complications and less conve-
nience. These splints fix the legs of the child in flexion and ab-
duction using a hard plastic splint. One study reported excellent
results with the Von Rosen splint but the quality of evidence was
limited (Heikkilä 1988). Other static splints include the Denis
Browne bar (which splints the hips in abduction and flexion), the
Rhino brace, and the Tu bingen hip flexion splint (Ottobock
splint).
The Frejka pillow is a further alternative, which is described as
a non-static splinting technique. This is widely used in Norway.
The pillow is a further form of abduction splint; that is, a simple
foam-rubber pillow that is strapped to the child to flex and abduct
the legs. The legs are fixed in abduction though not rigidly fixed.
The argument for the use of this splint is that it is easy to use,
needing less specialist supervision than other splints (Hinderaker
1992), which is better suited to the very disperse populations (i.e.
Norway). However, there are concerns about high complications
and treatment failures.
All splints are applied by an individual with specialist knowledge of
the use of these devices, which is typically a children’s orthopaedic
surgeon, an extended scope practitioner (physiotherapist or nurse
with specialist training), or an orthotist. The splint is worn for a
period of time defined by local policy, which will depend upon
the appearance of the hip; typically this is between six and 16
weeks. Throughout the period of splinting, ultrasound scans are
performed at regular intervals (typically between one and three
weeks, depending upon the practitioner and type of splint used)
to monitor progression. At the end of treatment, some centres
immediately discontinue the use of the splint, whilst other centres
’wean’ the splint and often advise treatment at night-time only for
a period of time. Children are then monitored according to local
policy, for a time period between three years and 16 years.
There is no national or international consensus of type of splint,
duration of splinting, weaning versus complete cessation, and
long-term follow-up.
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How the intervention might work
The interventions seek to direct the femoral head (ball) into the
acetabulum (socket), thereby promoting the development of the
joint. In infants, both femoral head and acetabulum are malleable
and will readily undergo plastic deformation. With both the ac-
etabulum and femoral head appropriately aligned, plastic defor-
mation will ensue, to enable both head and socket to form the
appropriate shape. For hips that have not sufficiently developed in
utero, splints position the hips in flexion and abduction to achieve
the optimal position for hip development. Splints can be either
dynamic splints (i.e. Pavlik splint), whereby the child is free to
move his or her legs within the range permitted by the splint, or
fixed (i.e. Von Rosen splint), whereby the child’s legs are fixed in
position to achieve the optimal position.
Why it is important to do this review
There is considerable variation in the non-operative management
of DDH (Tomlinson 2016). Treatment varies by country, institu-
tion, and even surgeon.Non-operativemanagement is not without
complication. Therefore, it is important to determine an optimal
strategy that achieves the greatest successes (i.e. avoids subsequent
operative interventions), whilst minimising complications related
to splinting (which includes AVN and femoral nerve palsy). It is
also important to identify whether there are particular subgroups
for whom the optimal management strategy may differ.
O B J E C T I V E S
To determine the role of splinting and the optimal treatment strat-
egy for the non-operative management of DDH in children under
six months of age. To identify if there are particular subgroups of
patients for whom the optimal management strategy may differ.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Randomised controlled trials (RCTs), quasi-RCTs, and
cluster-RCTs.
2. Prospective and retrospective non-randomised controlled
studies and cohort studies. We will consider non-randomised
trials for inclusion, as we expect that the number of randomised
trials in this population will be limited.
Types of participants
Children with all severities of DDH who are under six months of
age.
If studies include children over six months of age, we will contact
the study authors to obtain data on children under six months of
age.
We will exclude children with neurodevelopmental problems or
neuromuscular syndromes.
Types of interventions
1. Dynamic splinting (i.e. Pavlik harness, Frejka pillow).
2. Static splinting (e.g. Von Rosen, Denis Browne bar, Rhino
brace, Tu bingen hip flexion splint (Ottobock splint)).
3. Double nappies.
4. No treatment or delayed treatment.
We will make the following comparisons.
1. Dynamic splinting versus delayed or none.
2. Static splinting versus delayed or none.
3. Double nappies versus delayed or none.
4. Dynamic versus static.
Types of outcome measures
Primary outcomes
1. Measurement of acetabular index at years 1, 2, and 5, as
determined by radiographs (angle).
2. Need for operative intervention (dichotomous):
i) to achieve reduction; and
ii) to address dysplasia.
3. Complications (dichotomous):
i) AVN (there are several grading systems, most
commonly “total” AVN (Salter 1969), and “partial” AVN (Gage
1972));
ii) femoral nerve palsy;
iii) other nerve palsies; and
iv) pressure areas on skin.
We will use the primary outcomes to populate the Summary of
findings’ table.
Secondary outcomes
1. Health economic assessment (including financial impact on
the family), as reported in the included studies.
2. Bonding between parents and child (including obstacles to
breastfeeding, problems with winding and bathing baby), as
reported in the included studies.
3. Motor skill development, as reported in the included
studies. Motor skills is an outcome that parents are concerned
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about, as tummy time’ affects both fine and gross motor skills,
and the use of splints interferes with tummy time’:
i) fine motor skill development; and
ii) gross motor skill development.
Search methods for identification of studies
Electronic searches
We will search the following electronic databases and trials regis-
ters.
1. Central Register of Controlled Trials (CENTRAL; current
issue) in the Cochrane Library, which includes the Cochrane
Developmental, Psychosocial and Learning Problems Group’s
Specialised Register.
2. MEDLINE Ovid (1946 onwards).
3. MEDLINE In-Process and Other Non-Indexed Citations
Ovid (current issue).
4. MEDLINE Epub Ahead of Print Ovid (current issue).
5. Embase Ovid (1974 onwards).
6. CINAHL Plus EBSCOhost (Cumulative Index to Nursing
and Allied Health Literature; 1937 onwards).
7. PEDro (Physiotherapy Evidence Database;
www.pedro.org.au).
8. Science Citation Index - Expanded Web of Science (SCI-
EXPANDED; 1970 onwards).
9. Conference Proceedings Citation Index - Science Web of
Science (CPCI-S; 1990 onwards).
10. Cochrane Database of Systematic Reviews (CDSR; current
issue), part of the Cochrane Library.
11. Database of Abstracts of Reviews of Effects (DARE; current
issue), part of the Cochrane Library.
12. Networked Digital Library of Theses and Dissertations
(NDLTD; search.ndltd.org/index.php).
13. ClinicalTrials.gov (clinicaltrials.gov).
14. World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP; www.who.int/ictrp/en).
We will search MEDLINE using the search strategy in Appendix
1. This strategywill be adapted for the other databases listed above.
We will not restrict the search by date, publication status, study
type, or language. We will seek translations if necessary.
Searching other resources
We will search the reference lists of included studies and any rel-
evant reviews identified by the electronic searches (see Electronic
searches). We will also contact study authors to ask if they know
of any other studies, including those that are ongoing and un-
published, and will handsearch Orthopaedic Proceedings, which is a
source of abstracts frommajor international orthopaedic meetings
(bjjprocs.boneandjoint.org.uk).
Data collection and analysis
Selection of studies
Two review authors (one clinical expert and one methodologist,
e.g. KD or JK and AN or DP) will independently screen the titles
and abstracts of studies identified by the search strategy for eligibil-
ity (see Criteria for considering studies for this review). They will
then independently assess the full texts of potentially eligible stud-
ies.We will resolve any differences by discussion or by consulting a
third review author. We will list all studies excluded after full-text
assessment and their reasons for exclusion in a Characteristics
of excluded studies’ table. We will illustrate the study selection
process in a PRISMA flow diagram (Moher 2009).
Data extraction and management
Two review authors (one clinical expert and one methodologist,
e.g. KD or JK and AN or DP) will independently extract data
onto a prepiloted data extraction form (Appendix 2), which we
will manage in Microsoft Excel and refine accordingly. We will
resolve any disagreements through discussion or by consulting a
third review author.
Assessment of risk of bias in included studies
Two review authors (one clinical expert and one methodologist,
e.g. KD or JK and AN or DP) will independently assess RCTs and
quasi-RCTs for risk of bias, using Cochrane’s Risk of bias’ tool,
which is described in further detail in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve disagreements through discussion or by consult-
ing a third review author. The seven domains to be assessed are:
sequence generation, allocation sequence concealment, blinding
of participants and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting, and other
potential threats to validity. Review authors will assign a judge-
ment of either unclear, low, or high risk of bias (Appendix 3), along
with a justification for this decision in the Risk of bias’ tables.
If we identify any cluster-RCTs, we will also consider (i) recruit-
ment bias; (ii) baseline imbalance; (iii) loss of clusters; (iv) incor-
rect analysis; and (v) comparability with individually randomised
trials.
Due to our expectation that most studies we will identify will be
observational in nature, we will assess the risk of bias for non-ran-
domised studies using the recently developed ROBINS-I (Risk Of
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Bias In Non-randomised Studies - of Interventions) tool (Sterne
2016); for two outcomes of interest (need for surgical open re-
duction and acetabular index at one year) in each study, we will
perform a separate ’Risk of bias’ assessment. This tool considers
seven domains of bias: two domains of bias pre-intervention (bias
due to confounding and bias in selection of participants into the
study), one domain of bias at intervention (bias in the classifica-
tion of interventions), and four domains of bias postintervention
(bias due to departures from intended interventions, bias due to
missing data, bias in measurement of outcomes, and bias in selec-
tion of the reported result). Central to implementing ROBINS-
I is the consideration of confounding factors and cointerventions
that have the potential to lead to bias.
Important confounders of interest in this Cochrane Review in-
clude the following.
1. Age of child at intervention (i.e. harness commencement).
2. Proportion of females.
3. Ethnicity of the participants (or if not stated, the country in
which the study was conducted).
4. Clinical assessment of the hip. Dislocated hip (reducible or
not reducible), clinically unstable hip (i.e. dislocatable), or
clinically stable hip.
5. Ultrasound assessment of the hip. Acetabular dysplasia
assessed using the alpha angle according to Graf classification of
hip: I (normal), IIa or IIb (centred hip, 50 to 60 degrees of
dysplasia), IIc (centred hip 43 to 50 degrees of dysplasia), III (de-
centred hip), and IV (dislocated hip).
6. Indication for ultrasound screening (i.e. breech presentation
in third trimester, family history of DDH, lower than normal
levels of amniotic fluid, click’ on clinical screening (abnormal
clinical examination producing click’ sound on hip
movements), unequal skin creases).
We will add to the above list any further confounders we identify
following assessment of the included studies, if appropriate, and
specify these confounders as post hoc. We do not anticipate that
there will be any important cointerventions to consider. Each of
the seven domains of bias contain signalling questions to facili-
tate judgements of risk of bias. The full signalling question and
response framework for each outcome is provided in Sterne 2016.
Following completion of the signalling questions, we will seek a
Risk of bias’ judgement for each domain and obtain an overall
Risk of bias’ judgement for each outcome and result being as-
sessed. Overall risk of bias has four categories ranging from low
risk of bias (the study is at low risk of bias across all domains) to
critical risk of bias (the study is at critical risk of bias in at least
one domain). If there is insufficient information to assess the risk
of bias in one or more key domains, but there is no indication
that there is any critical or serious risk of bias in any of the other
domains, then we will designate the overall classification as ’no
information’.
Measures of treatment effect
Dichotomous outcome data
We will summarise data from dichotomous outcomes (e.g. need
for operative intervention, femoral nerve palsy, AVN) using the
risk ratio (RR) and 95% confidence intervals (CIs).
AVN is measured using a grading system and therefore is cate-
gorical. If this is reported as categorical data within a trial, we
will use a clinical rating of two and above to define AVN, thereby
dichotomising the data. There are many different rating systems
for AVN, which are difficult to amalgamate. In all rating systems
type-I AVN is mild AVN that is clinically unimportant, as it com-
pletely heals without long-term consequence.We therefore plan to
dichotomise the outcome to the presence or absence of clinically
important AVN. If we are unable to compute an effect size, we
will provide a narrative description of the results.
Continuous outcome data
For continuous outcomes (e.g. bondingbetweenparents and child,
measurement of acetabular index, fine and grossmotor skills) mea-
sured on the same scale, we will compute the mean difference
(MD) and 95% CIs; if different measures are reported, we will
compute the standardised mean difference (SMD) and 95% CIs.
If we are unable to compute an effect size, we will provide a nar-
rative description of the results.
For measurement of acetabular index, less than 30 degrees is con-
sidered normal in children aged over six months, and less than 25
degrees for children aged 24 months. Under six months of age,
an alpha angle of the hip on ultrasound scan above 60 degrees is
considered normal.
Health economic assessment
We will provide a narrative description of the results of the health
economic assessment.
Unit of analysis issues
Cluster-RCTs
If we include cluster-RCTs in which the trial authors have not
accounted for the cluster in their analyses, wewill reduce the size of
each trial to its effective sample size by diving the original sample
size by the design effect (by using the average cluster size and
the intracluster correlation coefficient (ICC)). If the ICC value is
unavailable, we will impute it from a similar study, if possible. We
will then include the data in the latest version of Review Manager
5 (RevMan 5) (Review Manager 2014), using the generic inverse
variance method.
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Cross-over RCTs
We will exclude cross-over trials. These are not appropriate as
DHH is not a chronic condition.
Multiple groups
If a study includes more than two similar intervention groups,
we will combine them and compare them with the control arm,
creating a single pair-wise comparison. If a study includes more
than two dissimilar intervention groups, wewill include these arms
in the review separately, and halve the control group to ensure
there is no double counting of participants.
Dealing with missing data
We will contact the authors of the included studies for missing
data. For transparency, if we do not receive a reply, we will note
this in the Characteristics of included studies’ tables. If we can
not obtain missing statistics (i.e. standard deviations), or calculate
them from data reported in the trial report, thenwe will attempt to
impute them for similar studies. We will not attempt imputation
on missing participant data as we expect most studies to be non-
randomised studies.
Assessment of heterogeneity
We will assess clinical and methodological aspects of the included
studies to determine whether there is clinical or methodological
heterogeneity.
We will assess statistical heterogeneity visually by looking at the
forest plots. We will calculate the Chi² test and will use a P value
of less than (<) 0.10 to determine statistical significance due to
the low power of the test. We will also calculate the I² statistic
and 95% CIs, which describe the percentage of the variability in
effect estimates that is due to heterogeneity rather than sampling
error (chance) (Higgins 2003). We will use the thresholds below
for interpretation.
1. 0% to 40%: might not be important.
2. 30% to 60%: may represent moderate heterogeneity.
3. 50% to 90%: may represent substantial heterogeneity.
4. 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
If we include 10 or more studies in the review, we will construct
a funnel plot to assess for publication bias. However, it should be
noted that asymmetry in the funnel plot can be caused by other
reasons, such as heterogeneity. We will also use Egger’s test to
formally assess funnel plot asymmetry (Egger 1997).
In addition, we will complete anOutcomeReporting Bias in Trials
(ORBIT) matrix to help with the assessment of selective outcome
reporting (Kirkham 2010).
Data synthesis
We will analyse different study designs separately (RCTs, quasi-
RCTs, retrospective and prospective non-randomised studies). We
will use a fixed-effect analysis unless there is substantial hetero-
geneity (i.e. I² statistic value of greater than (>) 50%); in which
case, we will use a random-effects analysis as a sensitivity analysis
(see Sensitivity analysis) and report both results (we will also re-
port the Tau² value). We will use the inverse variance method. If
there is considerable heterogeneity (i.e. I² statistic value > 75%),
we will not conduct a meta-analysis, but will provide a narrative
description of the results.
We will assess the comparisons below.
1. Splint versus no treatment or delayed treatment.
2. Double nappies versus no treatment or delayed treatment.
Subgroup analysis and investigation of heterogeneity
If sufficient studies are available, we will consider conducting the
subgroup analyses listed below.
1. Age (birth to three months, three months to six months).
The splint is thought to work better in younger infants.
2. Sex (boys, girls). DDH is more common in girls.
3. Type of splint (Pavlik harness or Frejka pillow; Von Rosen
splint, Denis Browne bar, Rhino brace, Tu bingen hip flexion
splint (Ottobock splint)).
4. Clinical assessment of the hip (dislocated hip (reducible or
not reducible), clinically unstable hip (i.e. dislocatable), or
clinically stable hip).
5. Static ultrasound assessment of the hip. Acetabular
dysplasia assessed using the alpha angle according to Graf
classification of hip: I (normal), IIa or IIb (centred hip, 50 to 60
degrees of dysplasia), IIc (centred hip 43 to 50 degrees of
dysplasia), III (de-centred hip), and IV (dislocated hip).
6. Dynamic ultrasound assessment of the hip (normal or
abnormal (subluxed or dislocated) based on the assessment
criteria used).
7. Type of dysplasia (unilateral or bilateral disease). This is
important because bilateral dislocations are harder to treat and
there is a higher failure rate, which is thought to be because
neither of the hips form a stable base for the treatment.
Sensitivity analysis
We will conduct sensitivity analyses for our primary outcomes
from RCTs and quasi-RCTs only (Primary outcomes). We will as-
sess the impact on our results of excluding quasi-RCTs and studies
at unclear or high risk of bias. We will also conduct a sensitivity
analysis using a random-effects model when there is substantial
heterogeneity.
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GRADE
Two review authors (one clinical expert and one methodologist,
e.g. KD or JK and AN or DP) will independently assess the qual-
ity of the evidence using the GRADE approach by considering
the risk of bias, directness of evidence, heterogeneity, precision
of effect estimates, and risk of publication bias. We will resolve
disagreements through discussion with a third review author. We
will use the GRADEpro Guideline Development Tool (GDT),
GRADEpro GDT 2015, to create a Summary of findings’ table
for our primary outcomes (see Primary outcomes) for each com-
parison.
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A D D I T I O N A L T A B L E S
Table 1. Graf classification system1
Graf Sonographic hip type Bony roof Ossific rim Cartilage rim Alpha angle
Ia Mature Good Sharp Long and narrow, extends far
over femoral head
> 60
Ib Mature Good Usually blunt Short and broad, but covers
femoral head
> 60
IIa Physiological delay in
ossification > 3 months
(physiological imma-
ture but stable hips)
Deficient Rounded Covers femoral head 50 to 59
IIb Physiological delay in
ossification > 3 months
(inherently stable)
Deficient Rounded Covers femoral head 50 to 59
IIc Onpoint of dislocation
(unstable, requires im-
mediate treatment)
Deficient Rounded or flat Covers femoral head 43 to 49
IId Onpoint of dislocation Severley deficient Rounded or flat Compressed 43 to 49
IIIa Dislocated
(subluxation)
Poor Flat Displaced upwards and echo
poor
< 43
IIIb Dislocated
(subluxation)
Poor Flat Displaced upwards and more
reflective than femoral head
< 43
IV Dislocated (complete) Poor Flat Interposed < 43
1. Karnik 2007
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1 Hip Dislocation/
2 Hip Dislocation, Congenital/
3 (dislocat$ adj3 hip$).tw,kf.
4 ((dysplasia$ or dysplastic$) adj3 hip$).tw,kf.
5 ((sublux$ or sub-lux$) adj3 hip$).tw,kf.
6 Acetabul$.tw,kf.
7 (congenital$ adj3 hip$).tw,kf.
8 (developmental$ adj3 hip$).tw,kf.
9 (CDH or DDH.tw,kf.
10 or/1-9
11 exp infant/
12 (baby or babies or child$ or infant$ or newborn$ or neonat$ or p?ediatric$).tw.
13 or/11-12
14 10 and 13
15 orthopedic fixation devices/
16 splints/
17 orthosis$.tw,kf.
18 (splint$ or harness$ or brace$ or pillow$).
19 (“double napp$” or “double diaper$”).tw,kf.
20 (Otto Bock$ or Ottobock$).tw,kf.
21 Pavlik$.tw,kf.
22 Denis Browne$.tw,kf.
23 Tubingen.tw,kf.
24 Frejka$.tw,kf.
25 von Rosen.tw,kf.
26 abduct$.tw,kf.
27 or/15-26
28 14 and 27
Appendix 2. Data extraction template
Study identifier
(ID)
-
References
(* main reference)
-
Trial registry and ID -
Participant characteristics
Age -
Gender -
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(Continued)
Ethnicity -
Comorbidities -
Clinical assessment
of the hip. Dislo-
cated hip (reducible
or not reducible)
, clinically unsta-
ble hip (i.e. dislocat-
able), or clinically
stable hip
-
Ultrasound assess-
ment of the hip.
Acetabular dysplasia
assessed using the al-
pha angle according
toGraf classification
of hip: I (normal),
IIa or IIb (centred
hip, 50 to 60 de-
grees of dysplasia),
IIc (centred hip 43
to 50 degrees of dys-
plasia), III (de-cen-
tred hip), and IV
(dislocated hip)
-
Unilateral or bilat-
eral disease
-
Trial characteristics
Trial design -
Single centre or
multicentre
-
Country/countries -
How was partici-
pant eligibility de-
fined?
-
How many people
were randomised?
-
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(Continued)
Number of partici-
pants in each inter-
vention group
-
Number of partici-
pants who received
intended treatment
-
Number
of participants who
were analysed
-
Splint used (include
details of timing,
weaning, etc.)
-
Comparator (in-
clude details of tim-
ing, weaning, etc.)
-
Risk of bias
Item Comment Judgement
Allocation of inter-
vention
- High/low/unclear
Concealment of al-
location
- High/low/unclear
Blinding of partici-
pants and personnel
- High/low/unclear
Blinding of
outcome assessment
- High/low/unclear
Incomplete
outcome data
- High/low/unclear
Selective outcome
reporting
- High/low/unclear
Other potential
threats to validity
- High/low/unclear
Outcomes Intervention Control Time point
12Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Measurement of acetab-
ular index, as deter-
mined by radiographs
(angle)
- - 1 year/2 years/5 years/other (specify)
Need for operative in-
tervention to achieve re-
duction
- - -
Need for operative in-
tervention to address
dysplasia
- - -
Avascular necrosis (in-
clude grading system)
- - -
Femoral nerve palsy - - -
Other nerve palsies - - -
Health economic assess-
ment (including finan-
cial impact on the fam-
ily)
- - -
Bonding between par-
ents and child (includ-
ing obstacles to breast-
feeding, problems with
winding and bathing
baby)
- - -
Fine motor skill devel-
opment
- - -
Appendix 3. Criteria for judging risk of bias in the ‘Risk of bias’ assessment tool1
Random sequence generation
Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence
Criteria for the judgement of low risk of bias The study investigators describe a random component in the se-
quence generation process such as:
1. referring to a random number table;
2. using a computer random number generator;
3. coin tossing;
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(Continued)
4. shuffling cards or envelopes;
5. throwing dice;
6. drawing of lots; or
7. minimisation¹.
¹Minimisation may be implemented without a random element,
and this is considered to be equivalent to being random
Criteria for the judgement of high risk of bias The investigators describe a non-random component in the se-
quence generation process. Usually, the description would involve
some systematic, non-random approach, for example:
1. sequence generated by odd or even date of birth;
2. sequence generated by some rule based on date (or day) of
admission; or sequence generated by some rule based on hospital
or clinic record number.
Other non-random approaches happen much less frequently than
the systematic approaches mentioned above and tend to be ob-
vious. They usually involve judgement or some method of non-
random categorisation of participants, for example:
1. allocation by judgement of the clinician;
2. allocation by preference of the participant;
3. allocation based on the results of a laboratory test or a series
of tests; or
4. allocation by availability of the intervention.
Criteria for the judgement of unclear risk of bias There is insufficient information about the sequence generation
process to permit a judgement of low or high risk of bias
Allocation concealment
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment
Criteria for the judgement of low risk of bias Participants and investigators enrolling participants could not
foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation:
1. central allocation (including telephone, web-based and
pharmacy-controlled randomisation);
2. sequentially numbered drug containers of identical
appearance; or
3. sequentially numbered, opaque, sealed envelopes.
Criteria for the judgement of high risk of bias Participants or investigators enrolling participants could possibly
foresee assignments and thus introduce selection bias, such as al-
location based on:
1. using an open random allocation schedule (e.g. a list of
random numbers);
2. using assignment envelopes without appropriate safeguards
(e.g. if envelopes were unsealed or nonopaque or not
sequentially numbered);
3. alternation or rotation;
4. date of birth;
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(Continued)
5. case record number; or
6. any other explicitly unconcealed procedure.
Criteria for the judgement of unclear risk of bias Insufficient information to permit judgement of low or high risk
of bias. This is usually the case if the method of concealment is
not described or not described in sufficient detail to allow a defi-
nite judgement, for example, if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequen-
tially numbered, opaque, and sealed
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions by participants and personnel during the study
Criteria for the judgement of low risk of bias Any one of the following:
1. no blinding or incomplete blinding, but the review authors
judge that the outcome is not likely to be influenced by lack of
blinding; or
2. blinding of participants and key study personnel ensured,
and unlikely that the blinding could have been broken.
Criteria for the judgement of high risk of bias Any one of the following:
1. no blinding or incomplete blinding, and the outcome is
likely to be influenced by lack of blinding; or
2. blinding of key study participants and personnel
attempted, but likely that the blinding could have been broken,
and the outcome is likely to be influenced by lack of blinding.
Criteria for the judgement of unclear risk of bias Any one of the following:
1. insufficient information to permit judgement of low or
high risk of bias; or
2. the study did not address this outcome.
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by outcome assessors
Criteria for the judgement of low risk of bias Any one of the following:
1. no blinding of outcome assessment, but the review authors
judge that the outcome measurement is not likely to be
influenced by lack of blinding; or
2. blinding of outcome assessment ensured, and unlikely that
the blinding could have been broken.
Criteria for the judgement of high risk of bias Any one of the following:
1. no blinding of outcome assessment, and the outcome
measurement is likely to be influenced by lack of blinding; or
2. blinding of outcome assessment, but likely that the
blinding could have been broken, and the outcome
measurement is likely to be influenced by lack of blinding.
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(Continued)
Criteria for the judgement of unclear risk of bias Any one of the following:
1. insufficient information to permit judgement of low or
high risk of bias; or
2. the study did not address this outcome.
Incomplete outcome data
Attrition bias due to amount, nature, or handling of incomplete outcome data
Criteria for the judgement of low risk of bias Any one of the following:
1. no missing outcome data;
2. reasons for missing outcome data unlikely to be related to
true outcome (for survival data, censoring unlikely to be
introducing bias);
3. missing outcome data balanced in numbers across
intervention groups, with similar reasons for missing data across
groups;
4. for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk not enough to have
a clinically relevant impact on the intervention effect estimate;
5. for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes not enough to have a clinically relevant
impact on observed effect size; or
6. missing data have been imputed using appropriate
methods.
Criteria for the judgement of high risk of bias Any one of the following:
1. reason for missing outcome data likely to be related to true
outcome, with either imbalance in numbers or reasons for
missing data across intervention groups;
2. for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate;
3. for continuous outcome data, plausible effect size
(difference in means or standardised difference in means) among
missing outcomes enough to induce clinically relevant bias in
observed effect size;
4. ‘as-treated’ analysis done with substantial departure of the
intervention received from that assigned at randomisation; or
5. potentially inappropriate application of simple imputation.
Criteria for the judgement of unclear risk of bias Any one of the following:
1. insufficient reporting of attrition or exclusions to permit
judgement of low or high risk of bias (e.g. number randomised
not stated, no reasons for missing data provided); or
2. the study did not address this outcome.
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(Continued)
Selective reporting
Reporting bias due to selective outcome reporting
Criteria for the judgement of low risk of bias Any of the following:
1. the study protocol is available and all of the study’s
prespecified (primary and secondary) outcomes that are of
interest in the review have been reported in the prespecified way;
or
2. the study protocol is not available but it is clear that the
published reports include all expected outcomes, including those
that were prespecified (convincing text of this nature may be
uncommon).
Criteria for the judgement of high risk of bias Any one of the following:
1. not all of the study’s prespecified primary outcomes have
been reported;
2. one or more primary outcomes is reported using
measurements, analysis methods or subsets of the data (e.g.
subscales) that were not prespecified;
3. one or more reported primary outcomes were not
prespecified (unless clear justification for their reporting is
provided, such as an unexpected adverse effect);
4. one or more outcomes of interest in the review are reported
incompletely so that they cannot be entered in a meta-analysis; or
5. the study report fails to include results for a key outcome
that would be expected to have been reported for such a study.
Criteria for the judgement of unclear risk of bias Insufficient information to permit judgement of low or high risk
of bias. It is likely that most studies will fall into this category
Other bias
Bias due to problems not covered elsewhere in the table
Criteria for the judgement of low risk of bias The study appears to be free of other sources of bias.
Criteria for the judgement of high risk of bias There is at least one important risk of bias. For example, the study:
1. had a potential source of bias related to the specific study
design used;
2. has been claimed to have been fraudulent; or
3. had some other problem.
Criteria for the judgement of unclear risk of bias There may be a risk of bias, but there is either:
1. insufficient information to assess whether an important risk
of bias exists; or
2. insufficient rationale or evidence that an identified problem
will introduce bias.
1. Taken from Higgins 2011
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